Tactile Systems Technology (NASDAQ:TCMD) Posts Quarterly Earnings Results

Tactile Systems Technology (NASDAQ:TCMD) issued its quarterly earnings results on Monday. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03, FiscalAI reports. The firm had revenue of $91.86 million for the quarter, compared to analysts’ expectations of $91.99 million. Tactile Systems Technology had a return on equity of 10.82% and a net margin of 6.68%.

Here are the key takeaways from Tactile Systems Technology’s conference call:

• Positive Sentiment: Lymphedema revenue grew 13% year over year to $81.8 million, with Medicare returning to 11% growth after prior-authorization timing disruptions stabilized. Management cited increased clinic visits, referring clinics, and sales-force productivity as drivers of continued momentum.
• Positive Sentiment: Tactile maintained 2026 revenue guidance of $360 million to $366 million and raised adjusted EBITDA guidance to $50 million-$52 million, supported by gross-margin expansion, strong cash generation, and expected operating leverage.
• Negative Sentiment: Airway-clearance revenue fell 25% to $10 million as several DME customers took longer than expected to work through excess inventory during the AffloVest transition. Management expects sequential improvement in Q4 but now projects full-year airway-clearance revenue to decline by mid- to high-single digits.
• Positive Sentiment: The company advanced its growth pipeline through FDA clearance of an expanded LymphaTech 3D Scanner indication, progress toward a Category III CPT code, the Flexitouch Pro 510(k) filing, and plans for a late-Q4 VA pilot of MyoSleeve.
• Neutral Sentiment: Management expects further long-term growth from improving referral-to-shipment conversion through AI-enabled order operations and the newly created COO role, but emphasized that new products, payer wins, and diagnostic reimbursement are likely to build gradually rather than create an immediate acceleration.

Tactile Systems Technology Price Performance

NASDAQ:TCMD opened at $24.78 on Wednesday. Tactile Systems Technology has a 1 year low of $20.53 and a 1 year high of $37.77. The stock’s fifty day moving average price is $22.75 and its two-hundred day moving average price is $25.88. The company has a market cap of $561.27 million, a P/E ratio of 22.20 and a beta of 0.95.

Insider Buying and Selling at Tactile Systems Technology

In other news, CEO Sheri Dodd sold 10,978 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $29.44, for a total transaction of $323,192.32. Following the sale, the chief executive officer directly owned 232,907 shares in the company, valued at $6,856,782.08. This represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TCMD. BTIG Research decreased their price objective on Tactile Systems Technology from $35.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen raised shares of Tactile Systems Technology from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings lowered shares of Tactile Systems Technology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.80.

Tactile Systems Technology Company Profile

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.